Summit slips on ivonescimab's apparent interim miss in sign of investor frustration

FierceBiotechSummit's PD-1xVEGF interim trial miss surprises analysts, shares tumble

Endpoints NewsAcelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China

Endpoints NewsSave the date: Premium subscriber-exclusive Post-Hoc Live

Endpoints NewsFDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal

BioWorldDermatology specialist Leo Pharma makes a $50M move into gene therapy

BioPharma DiveBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

FierceBiotechCBER chief Prasad steps aside, deputy takes the reins as search for successor continues

FierceBiotechJ&J axes $5B CAR-T dream months after touting best-in-disease efficacy

Endpoints NewsSummit slips on ivonescimab's apparent interim miss in sign of investor frustration

Endpoints NewsAmgen files update to Tavneos label as FDA escalates push to withdraw

FierceBiotechChutes & Ladders—Astellas appoints new top strategist from Sanofi Japan

FierceBiotechLigand tries to disembark from part of Viking pact, alleging contract breach